Treating either K562/Adr or HL-60/Adr cells with CEP did not modify PI4KA expression at the protein level (Figure 5A) but significantly decreased kinase activity of PI4KA and the production of PtdIns4P both in leukemia-resistant cell lines and patient samples (Figure 5B-C andFigure S11). This evidence concerns the gene PI4KA and leukemia.